By Blessing Nweke
A U.S. Food and Drug Administration (FDA) advisory panel has voted to recommend easing restrictions on several unapproved peptide therapies, including the widely discussed BPC-157, despite objections from FDA scientists and other medical experts over limited evidence of their safety and effectiveness.
The panel narrowly supported allowing BPC-157 and several other peptides to be considered for use by licensed compounding pharmacies. The recommendation is not legally binding, but it could influence future FDA decisions on whether the substances should become more widely available through compounded prescriptions.
Peptides are short chains of amino acids that have gained popularity online for claims ranging from faster injury recovery and wound healing to anti-aging and improved metabolism. However, many of these products have not undergone the rigorous clinical testing required for FDA approval, and experts say scientific evidence supporting many of the advertised benefits remains limited.
FDA scientists argued against loosening restrictions, warning that the available research does not adequately establish the drugs’ safety, effectiveness or quality. Critics also expressed concern that broader access could lead consumers to mistakenly believe the products have received full FDA approval.
Supporters of the move contend that regulated access through compounding pharmacies would provide a safer alternative to the growing gray market, where many consumers currently purchase peptides from unverified suppliers. They argue physician oversight and manufacturing standards could reduce potential risks.
The FDA is expected to review the advisory panel’s recommendations before making a final decision. Even if restrictions are eased, the peptides would remain unapproved drugs and would still lack formal FDA authorization for general medical use.
Original article
Comments